Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study

David Price, Richard J. Martin, Neil Barnes, Paul Dorinsky, Elliot Israel, Nicolas Roche, Alison Chisholm, Elizabeth V. Hillyer, Linda Kemp, Amanda J. Lee, Julie von Ziegenweidt, Gene Colice

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background
Long-term randomized trials comparing asthma outcomes between inhaled corticosteroids in real-world populations are lacking. As such, rigorously conducted observational studies to complement the findings of randomized trials are needed.

Objective
We sought to compare asthma-related outcomes over 1 year as recorded in a large primary care database for patients aged 5 to 60 years receiving a first prescription (initiation population) or dose increase (step-up population) of hydrofluoroalkane (HFA)-beclomethasone or fluticasone.

Methods
We used a retrospective matched cohort study in which patients were matched on baseline demographic and disease severity measures. Coprimary outcomes were asthma control (a composite measure comprising no unplanned visit or hospitalization for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and exacerbation rate.

Results
More than 80% of patients in each population achieved asthma control; 10% and 16% of patients in the initiation and step-up populations, respectively, received add-on or combination therapy during the year. Fluticasone was prescribed at significantly higher doses than HFA-beclomethasone for both populations (P = .001). In the initiation population (n = 1319 in each cohort) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.30 (95% CI, 1.02-1.65) relative to fluticasone. In the step-up population (cohorts: n = 250) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.22 (95% CI, 0.66-2.26). Exacerbation rates were similar between cohorts.

Conclusions
In a real-world setting patients receiving HFA-beclomethasone had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone.
Original languageEnglish
Pages (from-to)511-518.e10
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume126
Issue number3
Early online date9 Aug 2010
DOIs
Publication statusPublished - Sep 2010

Keywords

  • adolescent
  • adult
  • androstadienes
  • anti-asthmatic agents
  • asthma
  • beclomethasone
  • child
  • child, preschool
  • dose-response relationship, drug
  • drug therapy, combination
  • female
  • humans
  • longitudinal studies
  • male
  • middle aged
  • practice guidelines as topic
  • retrospective studies
  • treatment outcome

Fingerprint Dive into the research topics of 'Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study'. Together they form a unique fingerprint.

  • Cite this

    Price, D., Martin, R. J., Barnes, N., Dorinsky, P., Israel, E., Roche, N., Chisholm, A., Hillyer, E. V., Kemp, L., Lee, A. J., von Ziegenweidt, J., & Colice, G. (2010). Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study. Journal of Allergy and Clinical Immunology, 126(3), 511-518.e10. https://doi.org/10.1016/j.jaci.2010.06.040